{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:15:31Z","timestamp":1790817331454,"version":"4.1.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To enhance the in vivo antitumor activity of adoptively transferred, CD19-specific chimeric antigen receptor (CAR)\u2013redirected cytotoxic T lymphocytes (CTLs), we studied the effect of restimulating CAR+ CTLs through their endogenous virus-specific T-cell antigen receptor (TcR) by the cotransfer of engineered T-cell antigen\u2013presenting cells (T-APCs). Using influenza A matrix protein 1 (MP1) as a model antigen, we show that ex vivo\u2013expanded CD4+ and CD8+ T-APCs expressing a hygromycin phosphotransferase-MP1 fusion protein (HyMP1) process and present MP1 to autologous human leukocyte antigen (HLA)\u2013restricted, MP1-specific CD4+ and CD8+ CTL precursors. The MP1-specific CTLs are amenable to subsequent genetic modification to express a CD19-specific CAR, designated CD19R, and acquire HLA-unrestricted reactivity toward CD19+ leukemia and lymphoma tumor targets while maintaining HLA-restricted MP1 specificity. The restimulation of MP1\u00d7CD19 dual-specific CTLs in vivo by the adoptive transfer of irradiated HyMP1+ T-APCs resulted in the enhanced antilymphoma potency of bispecific effector cells, as measured by elimination of the biophotonic signal of established firefly luciferase\u2013expressing Burkitt lymphoma xenografts in nonobese diabetic\/severe combined immunodeficiency (NOD\/scid) animals compared with control groups restimulated by Hy+MP1neg T-APCs. Engineered T-APCs are a novel and versatile antigen-delivery system for generating antigen-specific T cells in vitro and enhancing the in vivo effector functioning of CAR-redirected antitumor effector cells.<\/jats:p>","DOI":"10.1182\/blood-2004-03-1208","type":"journal-article","created":{"date-parts":[[2004,10,27]],"date-time":"2004-10-27T01:58:13Z","timestamp":1098842293000},"page":"1622-1631","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":90,"title":["Enhanced antilymphoma efficacy of CD19-redirected influenza MP1\u2013specific CTLs by cotransfer of T cells modified to present influenza MP1"],"prefix":"10.1182","volume":"105","author":[{"given":"Laurence J. N.","family":"Cooper","sequence":"first","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid","family":"Al-Kadhimi","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Marie","family":"Serrano","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Olivares","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Castro","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chung","family":"Chang","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Smith","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jensen","sequence":"additional","affiliation":[{"name":"From the Divisions of Pediatric Hematology-Oncology, Molecular Medicine, Hematology and Hematopoietic Cell Transplantation, and Bioinformatics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021217040880800_REF1","doi-asserted-by":"crossref","unstructured":"Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T-cells. Proc Natl Acad Sci U S A. 2002;99: 16168-16173.","DOI":"10.1073\/pnas.242600099"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333: 1038-1044.","DOI":"10.1056\/NEJM199510193331603"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298: 850-854.","DOI":"10.1126\/science.1076514"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Brodie SJ, Patterson BK, Lewinsohn DA, et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest. 2000;105: 1407-1417.","DOI":"10.1172\/JCI8707"},{"key":"2020021217040880800_REF5","doi-asserted-by":"crossref","unstructured":"Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996;2: 551-555.","DOI":"10.1038\/nm0596-551"},{"key":"2020021217040880800_REF6","doi-asserted-by":"crossref","unstructured":"Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999;170: 85-100.","DOI":"10.1111\/j.1600-065X.1999.tb01331.x"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 2003;21: 807-839.","DOI":"10.1146\/annurev.immunol.21.120601.141135"},{"key":"2020021217040880800_REF8","doi-asserted-by":"crossref","unstructured":"Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83: 117-158.","DOI":"10.1016\/S0065-230X(01)83005-0"},{"key":"2020021217040880800_REF9","unstructured":"Roessig C, Scherer SP, Baer A, et al. Targeting CD19 with genetically modified EBV-specific human T lymphocytes. Ann Hematol. 2002;(suppl 2): S42-S43."},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy. 2003;5: 131-138.","DOI":"10.1080\/14653240310001028"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003; 9: 279-286.","DOI":"10.1038\/nm827"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18: 676-684.","DOI":"10.1038\/sj.leu.2403302"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Gross G, Eshhar Z. Endowing T-cells with antibody specificity using chimeric T cell receptors. FASEB J. 1992;6: 3370-3378.","DOI":"10.1096\/fasebj.6.15.1464371"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J Immunol. 1998;160: 145-154.","DOI":"10.4049\/jimmunol.160.1.145"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T-cells from a single gene product. J Immunol. 1998;161: 2791-2797.","DOI":"10.4049\/jimmunol.161.6.2791"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood. 2001;98: 2364-2371.","DOI":"10.1182\/blood.V98.8.2364"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy. 2003;5: 211-226.","DOI":"10.1080\/14653240310001488"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer. 2003;3: 35-45.","DOI":"10.1038\/nrc971"},{"key":"2020021217040880800_REF19","doi-asserted-by":"crossref","unstructured":"Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T-cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR\u03b6 chain. J Immunol. 2004;172: 104-113.","DOI":"10.4049\/jimmunol.172.1.104"},{"key":"2020021217040880800_REF20","doi-asserted-by":"crossref","unstructured":"Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T-cells: implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant. 1998;4: 75-83.","DOI":"10.1053\/bbmt.1998.v4.pm9763110"},{"key":"2020021217040880800_REF21","doi-asserted-by":"crossref","unstructured":"Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99: 2009-2016.","DOI":"10.1182\/blood.V99.6.2009"},{"key":"2020021217040880800_REF22","unstructured":"Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Adoptively transferred bispecific T cells expanded in vivo by restimulation with a T-cell vaccine can treat established B-lineage malignancy [abstract]. Blood. 2003;102: 2292."},{"key":"2020021217040880800_REF23","doi-asserted-by":"crossref","unstructured":"Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003;101: 1637-1644.","DOI":"10.1182\/blood-2002-07-1989"},{"key":"2020021217040880800_REF24","doi-asserted-by":"crossref","unstructured":"Mahmoud MS, Fujii R, Ishikawa H, Kawano MM. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood. 1999;94: 3551-3558.","DOI":"10.1182\/blood.V94.10.3551.422k08_3551_3558"},{"key":"2020021217040880800_REF25","unstructured":"Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, Clifford P. Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines. Cancer Res. 1968;28: 1300-1310."},{"key":"2020021217040880800_REF26","doi-asserted-by":"crossref","unstructured":"Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics. 1985;2: 235-246.","DOI":"10.1007\/BF00375376"},{"key":"2020021217040880800_REF27","doi-asserted-by":"crossref","unstructured":"Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood. 1980;56: 344-350.","DOI":"10.1182\/blood.V56.3.344.344"},{"key":"2020021217040880800_REF28","doi-asserted-by":"crossref","unstructured":"Gotch F, Rothbard J, Howland K, Townsend A, McMichael A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature. 1987;326: 881-882.","DOI":"10.1038\/326881a0"},{"key":"2020021217040880800_REF29","doi-asserted-by":"crossref","unstructured":"Larsson M, Messmer D, Somersan S, et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T-cells. J Immunol. 2000;165: 1182-1190.","DOI":"10.4049\/jimmunol.165.3.1182"},{"key":"2020021217040880800_REF30","doi-asserted-by":"crossref","unstructured":"Morrison J, Elvin J, Latron F, et al. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. Eur J Immunol. 1992;22: 903-907.","DOI":"10.1002\/eji.1830220404"},{"key":"2020021217040880800_REF31","doi-asserted-by":"crossref","unstructured":"Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000;1: 49-55.","DOI":"10.1006\/mthe.1999.0012"},{"key":"2020021217040880800_REF32","doi-asserted-by":"crossref","unstructured":"David HA. Robust estimation in the presence of outliers. Robustness in Statistics. 1979;1: 61-74.","DOI":"10.1016\/B978-0-12-438150-6.50011-X"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Guttman I, Smith DE. Investigation of rules for dealing with outliers in small samples from the normal distribution I: estimation of the mean. Technometrics. 1969;11: 527-550.","DOI":"10.1080\/00401706.1969.10490710"},{"key":"2020021217040880800_","unstructured":"R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2003."},{"key":"2020021217040880800_REF35","unstructured":"Hothorn T, Hornik K. exactRankTests package for R. Available at: http:\/\/cran.r-project.org. Accessed November 23, 2004."},{"key":"2020021217040880800_REF36","unstructured":"Streitberg B, Ro\u0308hmel J. Exact distributions for permutations and rank tests: an introduction to some recently published algorithms. Statistical Software Newsletter. 1986;12: 10-17."},{"key":"2020021217040880800_REF37","doi-asserted-by":"crossref","unstructured":"Uetsuki T, Naito A, Nagata S, Kaziro Y. Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha. J Biol Chem. 1989;264: 5791-5798.","DOI":"10.1016\/S0021-9258(18)83619-5"},{"key":"2020021217040880800_REF38","doi-asserted-by":"crossref","unstructured":"Lehner PJ, Wang EC, Moss PA, et al. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T-cells bearing the V beta 17 gene segment. J Exp Med. 1995;181: 79-91.","DOI":"10.1084\/jem.181.1.79"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Lawson TM, Man S, Williams S, Boon AC, Zambon M, Borysiewicz LK. Influenza A antigen exposure selects dominant Vbeta17+ TCR in human CD8+ cytotoxic T cell responses. Int Immunol. 2001;13: 1373-1381.","DOI":"10.1093\/intimm\/13.11.1373"},{"key":"2020021217040880800_REF40","doi-asserted-by":"crossref","unstructured":"Moss PA, Moots RJ, Rosenberg WM, Rowland-Jones SJ, Bodmer HC, McMichael AJ. Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. Proc Natl Acad Sci U S A. 1991;88: 8987-8990.","DOI":"10.1073\/pnas.88.20.8987"},{"key":"2020021217040880800_REF41","doi-asserted-by":"crossref","unstructured":"Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin Exp Metastasis. 2003;20: 733-744.","DOI":"10.1023\/B:CLIN.0000006815.49932.98"},{"key":"2020021217040880800_REF42","doi-asserted-by":"crossref","unstructured":"Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993;259: 368-370.","DOI":"10.1126\/science.7678351"},{"key":"2020021217040880800_","doi-asserted-by":"crossref","unstructured":"Cardoso AA, Veiga JP, Ghia P, et al. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. Blood. 1999;94: 3531-3540.","DOI":"10.1182\/blood.V94.10.3531.422k14_3531_3540"},{"key":"2020021217040880800_REF44","doi-asserted-by":"crossref","unstructured":"D'Amico G, Vulcano M, Bugarin C, et al. Activation of BCP-ALL cells through CD40 generates IL-10 producing, IL-12 defective APC inducing allogeneic T-cell anergy. Blood. 2004;104: 744-751.","DOI":"10.1182\/blood-2003-11-3762"},{"key":"2020021217040880800_REF45","doi-asserted-by":"crossref","unstructured":"Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol. 2004;172: 3437-3446.","DOI":"10.4049\/jimmunol.172.6.3437"},{"key":"2020021217040880800_REF46","doi-asserted-by":"crossref","unstructured":"Nichol KL. Live attenuated influenza virus vaccines: new options for the prevention of influenza. Vaccine. 2001;19: 4373-4377.","DOI":"10.1016\/S0264-410X(01)00143-8"},{"key":"2020021217040880800_REF47","doi-asserted-by":"crossref","unstructured":"Berger C, Huang ML, Gough M, Greenberg PD, Riddell SR, Kiem HP. Nonmyeloablative immunosuppressive regimen prolongs in vivo persistence of gene-modified autologous T cells in a nonhuman primate model. J Virol. 2001;75: 799-808.","DOI":"10.1128\/JVI.75.2.799-808.2001"},{"key":"2020021217040880800_REF48","doi-asserted-by":"crossref","unstructured":"Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2: 216-223.","DOI":"10.1038\/nm0296-216"},{"key":"2020021217040880800_REF49","doi-asserted-by":"crossref","unstructured":"Mannie MD, Walker MR. Feedback activation of T-cell antigen-presenting cells during interactions with T-cell responders. J Leukoc Biol. 2001;70: 252-260.","DOI":"10.1189\/jlb.70.2.252"},{"key":"2020021217040880800_REF50","doi-asserted-by":"crossref","unstructured":"Atanackovic D, Matsuo M, Ritter E, et al. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods. 2003;278: 57-66.","DOI":"10.1016\/S0022-1759(03)00209-6"},{"key":"2020021217040880800_REF51","doi-asserted-by":"crossref","unstructured":"Kershaw MH, Westwood JA, Hwu P. Dual-specific T-cells combine proliferation and antitumor activity. Nat Biotechnol. 2002;20: 1221-1227.","DOI":"10.1038\/nbt756"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/4\/1622\/1706485\/zh800405001622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/105\/4\/1622\/1706485\/zh800405001622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T18:25:15Z","timestamp":1682792715000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/105\/4\/1622\/20353\/Enhanced-antilymphoma-efficacy-of-CD19redirected"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,15]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,2,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-03-1208","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,15]]}}}